8:00 am Morning Refreshments
8:55 am Chair’s Opening Remarks
DEMONSTRATING STATE-OF-THE-ART CNS DEGRADERS TO SUPERCHARGE DEVELOPMENT INTO 2024
9:00 am Navigating the Crucial Clinical Trial Design Considerations for CNS Protein Degraders
Synopsis
- Outlining experiences of carrying out long-lasting clinical trials for neurodegenerative indications with older patient populations
- Overcoming dosage and toxicology considerations before entering clinical trials
- Discussing the use of biomarkers to monitor brain penetration, target engagement and degradation efficacy
9:30 am Contextualizing Historical Case Studies of Protein Degradation Clinical Trials Against Neuro-Oncology Targets
Synopsis
- Lessons learned from neuro-oncology trials assessing an agent’s ability to cross the blood brain barrier
- What are the important considerations to account for in developing degraders for CNS targets?
- Outlining clinical trial design in oncology and neuro-oncology studies
10:00 am Showcasing Preclinical Proof of Concept of Autophagy-Mediated Protein Degradation Against Aggregated Targets in the Brain
Synopsis
- Evaluating AUTOTAC engagement and efficacy in targeted CNS protein degradation
- Detailing AUTOTAC design to ensure controlled autophagy degradation via P62 targeting
- Explaining experimental set-up and model systems utilized for testing AUTOTAC therapies
10:30 am Speed Networking
Synopsis
With more CNS and TPD companies expanding into the field, this session is a great opportunity
to introduce yourself to CNS and TPD experts from leading drug developers. This session is the
ideal opportunity to get face-to-face time with the brightest minds in the protein degrader field
to establish meaningful relationships.
11:00 am Morning Break & Networking
PROTEASOME & BEYOND: DETAILING STRATEGIES FOR DEGRADING INTRACELLULAR & EXTRACELLULAR CNS PROTEINS
11:30 am Panel Discussion: Striving Beyond Proteasome Capacity: Debating the Different Strategies for Protein Degradation in CNS
Synopsis
- Outlining the theoretical biological limitations of proteasome-mediated degradation – does this correlate with reported PROTAC capabilities?
- Understanding the potential of lysosome and autophagy-mediated degradation to target extracellular, aggregated CNS disease proteins
- Weighing up strategies of preventing new aggregates forming against degrader existing disease proteins – which is the best route to go?
12:00 pm Harnessing Autophagy for Lysosomal Targeted Degradation
Synopsis
- Identification, development, and utility of small molecule ligands targeting the autophagy machinery
- Targeting the autophagy initiation complex with bifunctional molecules to control autophagy pathway activity
- Leveraging autophagy to degrade pathogenic targets associated with neurodegeneration and aging related diseases
12:30 pm Lunch & Networking
1:30 pm Showcasing Development of Degraders to Target Extracellular Pathological Proteins Via Lysosomal Degradation
Synopsis
- Targeting extracellular proteins and introduction to degradation technology
- Designing degraders inducing lysosomal-mediated degradation for CNS applications
- Showcasing preclinical data of degrader mechanism of action
2:00 pm Outlining Design & Development of a Novel Class of Degrader Targeting Partially Folded Prion Proteins
Synopsis
- Explaining design rationale behind the paradigm of designing protein degraders by targeting protein folding intermediates
- Outlining screening and in vitro development of a molecule targeting a non-native folding intermediate of the cellular prion protein
- Exploring future development and applications of technology to the degrader field
2:30 pm Afternoon Break & Scientific Poster Session
Synopsis
This is an informal session to introduce yourself to experts across leading TPD and CNS biopharma. With an audience of engaged enthusiasts, enjoy face-to-face time and share your work with many of the brightest minds, displaying scientific posters capturing the main advancements and challenges across CNS protein degraders to establish meaningful business relationships.
MAPPING LOCATIONS & UNDERSTANDING MECHANISMS OF ACTION FOR BRAIN-SPECIFIC E3 LIGASES
3:00 pm Pushing the Boundary of Global Proteomic Approaches to Identify Off-Target Degradation & Degrader Interactions
Synopsis
- Analyzing the capability of global proteomic approaches to capture degrader global expression, target engagement and downstream mechanism of action
- Detailing past case studies and learnings from oncology, cardiovascular and respiratory investigations
- Applying proteomic strategies to CNS targets to identify off-target degradation outside the brain
3:30 pm Exploring Small Molecule Degraders of SUMO1 & APP in Brain Cancer & Alzheimer’s Patients Via Cul1 E3 Ligase & Lysosomal Pathway
Synopsis
- Outlining degrader binding and degradation via CAPRIN1-CUL1 E3 ligase demonstrated in cancer
- Identifying compounds targeting and reducing amyloid beta 42 in Alzheimer’s neuron models
- Explaining CAPRIN1 and APP degradation mechanism through neuronal lysosomes
4:00 pm Chair’s Closing Remarks
4:15 pm End of Conference Day One
Download the Full Event Guide for more information on:
- 18+ Expert Speakers
- 2x in-depth, interactive workshops
- & much more!
